119 related articles for article (PubMed ID: 25847298)
1. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Christian BA; Poi M; Jones JA; Porcu P; Maddocks K; Flynn JM; Benson DM; Phelps MA; Wei L; Byrd JC; Wegener WA; Goldenberg DM; Baiocchi RA; Blum KA
Br J Haematol; 2015 Jun; 169(5):701-10. PubMed ID: 25847298
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
4. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
5. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20
Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
[TBL] [Abstract][Full Text] [Related]
6. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
7. Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013.
Eyckmans T; Wollants E; Janssens A; Schoemans H; Lagrou K; Wauters J; Maertens J
Emerg Infect Dis; 2014 May; 20(5):913-5. PubMed ID: 24751368
[No Abstract] [Full Text] [Related]
8. Anti-CD20 therapy for older patients with B-cell non-Hodgkin lymphoma in the context of epidemic normalization.
Zhang D; Xu S
Asian J Surg; 2024 Apr; ():. PubMed ID: 38599972
[No Abstract] [Full Text] [Related]
9. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Borthakur G; Dombret H; Schafhausen P; Brummendorf TH; Boissel N; Jabbour E; Mariani M; Capolongo L; Carpinelli P; Davite C; Kantarjian H; Cortes JE
Haematologica; 2015 Jul; 100(7):898-904. PubMed ID: 25887498
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
14. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
15. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.
Nabhan C; Byrtek M; Rai A; Dawson K; Zhou X; Link BK; Friedberg JW; Zelenetz AD; Maurer MJ; Cerhan JR; Flowers CR
Br J Haematol; 2015 Jul; 170(1):85-95. PubMed ID: 25851937
[TBL] [Abstract][Full Text] [Related]
16. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.
Ferreri AJ; Sassone M; Kiesewetter B; Govi S; Scarfò L; Donadoni G; Raderer M
Ann Oncol; 2015 Aug; 26(8):1760-5. PubMed ID: 25935794
[TBL] [Abstract][Full Text] [Related]
17. Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
Miller CR; Stephens D; Ruppert AS; Racke F; McFaddin A; Breidenbach H; Lin HJ; Waller K; Bannerman T; Jones JA; Woyach JA; Andritsos LA; Maddocks K; Zhao W; Lozanski G; Flynn JM; Grever M; Byrd JC; Heerema NA
Br J Haematol; 2015 Jul; 170(2):200-7. PubMed ID: 25891862
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB; Rizvi NA; Hui R; Leighl N; Balmanoukian AS; Eder JP; Patnaik A; Aggarwal C; Gubens M; Horn L; Carcereny E; Ahn MJ; Felip E; Lee JS; Hellmann MD; Hamid O; Goldman JW; Soria JC; Dolled-Filhart M; Rutledge RZ; Zhang J; Lunceford JK; Rangwala R; Lubiniecki GM; Roach C; Emancipator K; Gandhi L;
N Engl J Med; 2015 May; 372(21):2018-28. PubMed ID: 25891174
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Assouline S; Buccheri V; Delmer A; Gaidano G; McIntyre C; Brewster M; Catalani O; Hourcade-Potelleret F; Sayyed P; Badoux X
Br J Clin Pharmacol; 2015 Nov; 80(5):1001-9. PubMed ID: 25900065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
